8 results match your criteria: "Hospital Universitario Centro Dermatológico Federico Lleras Acosta E.S.E.[Affiliation]"
Trop Med Infect Dis
October 2023
Grupo DermatologÃa Tropical, Hospital Universitario Centro Dermatológico Federico Lleras Acosta E.S.E, Bogotá 111511, Colombia.
Background: Single nucleotide variants in toll-like receptor genes play a crucial role in leprosy susceptibility or resistance.
Methods: With an epidemiology case-control study, associations between SNVs rs5743618 in TLR1, rs5743708 in TLR2, and rs5743810 in TLR6 and overall susceptibility for leprosy were estimated in 114 cases and 456 controls. Following that, stratified analysis was performed.
PLoS Negl Trop Dis
January 2023
Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali, Colombia.
Background: Treatment guidance for children and older adult patients affected by cutaneous leishmaniasis (CL) is unclear due to limited representation of these groups in clinical trials.
Methods: We conducted a collaborative retrospective study to describe the effectiveness and safety of antileishmanial treatments in children ≤ 10 and adults ≥ 60 years of age, treated between 2014 and 2018 in ten CL referral centers in Latin America.
Results: 2,037 clinical records were assessed for eligibility.
Cancer Diagn Progn
January 2022
General Dermatology Group, Hospital Universitario Centro Dermatológico Federico Lleras Acosta E.S.E, Bogotá, Colombia.
Background/aim: Non-melanoma skin cancer is the most common cancer in the world. Somatic mutations in the TP53 gene are associated with the development of this cancer. To describe mutations in exons 5-8 of the TP53 gene in a sample of Colombian patients with non-melanoma skin cancer.
View Article and Find Full Text PDFIn Vivo
June 2021
General Dermatology Group, Hospital Universitario Centro Dermatológico Federico Lleras Acosta E.S.E, Bogotá, Colombia
PLoS One
December 2019
Centro de Investigaciones en MicrobiologÃa y ParasitologÃa Tropical (CIMPAT), Facultad de Ciencias, Universidad de los Andes, Bogotá, Colombia.
In Colombia, nine species of parasites of the genus Leishmania circulate in more than 20 sand fly species, putting at risk of contracting the disease approximately 60% of the population. The Federico Lleras Acosta Dermatological Center, a reference center in Colombia, has been treating patients with cutaneous and mucosal leishmaniasis for more than 15 years, identifying the infecting Leishmania species from different clinical samples, and recording systematically all the epidemiological and geographic information related to each diagnosed patient. With this valuable information, the objective of this work was to perform a long term and large-scale study, aiming to identify the Leishmania species circulating in Colombia from clinical samples from 1999 to 2016, and to assess their current and potential spatial distribution.
View Article and Find Full Text PDFPediatr Dermatol
July 2018
Department of Dermatology, Hospital ClÃnico Universitario, Valencia, Spain.
Amphotericin B (AmB) is a recommended medication for the treatment of cutaneous and mucosal leishmaniasis in cases of therapeutic failure with first-line medications; however, little is known about the in vitro susceptibility to AmB of clinical isolates of the subgenus Viannia, which is most prevalent in South America. This work aimed to determine the in vitro susceptibility profiles to AmB of clinical isolates of the species L. (V.
View Article and Find Full Text PDFActas Dermosifiliogr (Engl Ed)
April 2018
Fundación Universitaria Sanitas, Bogotá, D.C., Colombia.